Versartis Company Profile (NASDAQ:VSAR)

About Versartis

Versartis logoVersartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's product pipeline includes VRS-317 and XTEN Technology. The Company's VRS-317 combines the rhGH amino acid sequence utilized in approved rhGH products with a half-life extension technology, XTEN, to enable less frequent administration. The XTEN technology consists of hydrophilic amino acids added at the genetic level as part of the manufacturing process. The Company's XTEN is a recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins in a tunable manner. The XTEN sequence consists of hydrophilic amino acids and possesses various additional properties, which are used for the development of protein pharmaceuticals.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VSAR
  • CUSIP:
Key Metrics:
  • Previous Close: $12.54
  • 50 Day Moving Average: $11.62
  • 200 Day Moving Average: $9.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.89
  • P/E Growth: 0.00
  • Market Cap: $375.47M
  • Outstanding Shares: 29,541,000
  • Beta: 2.23
Additional Links:
Companies Related to Versartis:

Analyst Ratings

Consensus Ratings for Versartis (NASDAQ:VSAR) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $20.00 (57.36% upside)

Analysts' Ratings History for Versartis (NASDAQ:VSAR)
DateFirmActionRatingPrice TargetDetails
8/11/2016Citigroup Inc.Set Price TargetBuy$17.00 -> $23.00View Rating Details
8/11/2016Canaccord GenuitySet Price TargetBuy$28.00View Rating Details
7/29/2016Credit Suisse Group AGReiterated RatingSell$9.00View Rating Details
4/30/2016Morgan StanleyReiterated RatingHoldView Rating Details
4/7/2016Northland SecuritiesInitiated CoverageOutperformView Rating Details
2/2/2016Cowen and CompanyReiterated RatingBuyView Rating Details
5/10/2015SunTrust Banks Inc.Reiterated RatingBuy$50.00 -> $45.00View Rating Details
(Data available from 8/29/2014 forward)


Earnings History for Versartis (NASDAQ:VSAR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016Q2($0.78)($0.75)ViewN/AView Earnings Details
2/18/2016Q415($0.71)($0.69)ViewN/AView Earnings Details
10/29/2015Q3($0.79)($0.69)ViewN/AView Earnings Details
8/4/2015Q2($0.64)($0.67)ViewN/AView Earnings Details
5/6/2015($0.70)($0.79)ViewN/AView Earnings Details
2/12/2015Q414($0.53)($0.65)ViewN/AView Earnings Details
11/6/2014Q3 14($0.46)($0.57)ViewN/AView Earnings Details
5/5/2014Q114($6.37)($2.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Versartis (NASDAQ:VSAR)
Current Year EPS Consensus Estimate: $-3.23 EPS
Next Year EPS Consensus Estimate: $-1.61 EPS


Dividend History for Versartis (NASDAQ:VSAR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Versartis (NASDAQ:VSAR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/25/2016John VarianDirectorSell1,600$12.97$20,752.00View SEC Filing  
8/22/2016Jay ShepardCEOSell5,442$12.88$70,092.96View SEC Filing  
6/15/2016Joshua T BrummCFOSell1,448$10.63$15,392.24View SEC Filing  
6/15/2016Paul WestbergVPSell725$10.63$7,706.75View SEC Filing  
5/20/2016Joshua T BrummCFOSell1,265$7.87$9,955.55View SEC Filing  
4/21/2016Paul WestbergVPSell1,430$9.68$13,842.40View SEC Filing  
12/30/2015Joshua T BrummCFOSell990$12.44$12,315.60View SEC Filing  
12/30/2015Paul WestbergVPSell362$12.44$4,503.28View SEC Filing  
11/12/2015Joshua T BrummCFOBuy2,500$9.99$24,975.00View SEC Filing  
11/11/2015R Scott GreerDirectorBuy10,000$10.17$101,700.00View SEC Filing  
7/6/2015Paul WestbergVPSell2,400$15.00$36,000.00View SEC Filing  
6/3/2015Paul WestbergVPSell2,400$16.73$40,152.00View SEC Filing  
5/4/2015Paul WestbergVPSell2,400$17.47$41,928.00View SEC Filing  
4/14/2015Jeffrey L ClelandCEOSell8,000$20.13$161,040.00View SEC Filing  
4/6/2015Paul WestbergVPSell2,400$17.49$41,976.00View SEC Filing  
3/23/2015Jeffrey L ClelandCEOSell4,000$20.26$81,040.00View SEC Filing  
3/20/2015Jeffrey L ClelandCEOSell3,179$20.03$63,675.37View SEC Filing  
3/10/2015Jeffrey L ClelandCEOSell4,000$20.23$80,920.00View SEC Filing  
3/2/2015Jeffrey L ClelandCEOSell2,871$20.11$57,735.81View SEC Filing  
2/3/2015Paul WestbergVPSell5,000$17.40$87,000.00View SEC Filing  
1/27/2015Aisling Capital Iii LpMajor ShareholderBuy145,000$17.25$2,501,250.00View SEC Filing  
1/27/2015R Scott GreerDirectorBuy5,500$17.25$94,875.00View SEC Filing  
1/22/2015Shahzad MalikDirectorBuy55,000$17.25$948,750.00View SEC Filing  
1/12/2015Jeffrey L ClelandCEOSell4,000$22.85$91,400.00View SEC Filing  
1/5/2015Jeffrey L ClelandCEOSell4,000$21.94$87,760.00View SEC Filing  
1/5/2015Paul WestbergVPSell5,000$22.48$112,400.00View SEC Filing  
12/29/2014Jeffrey L ClelandCEOSell4,000$22.11$88,440.00View SEC Filing  
12/22/2014Jeffrey L ClelandCEOSell8,000$21.14$169,120.00View SEC Filing  
12/18/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell150,000$19.01$2,851,500.00View SEC Filing  
12/12/2014Paul WestbergVPSell10,000$18.55$185,500.00View SEC Filing  
11/24/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell17,207$18.02$310,070.14View SEC Filing  
11/21/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell26,793$18.04$483,345.72View SEC Filing  
11/20/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell9,000$18.32$164,880.00View SEC Filing  
11/18/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell191,362$19.38$3,708,595.56View SEC Filing  
11/13/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell12,438$19.43$241,670.34View SEC Filing  
11/12/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell36,200$19.42$703,004.00View SEC Filing  
9/29/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell12,556$20.02$251,371.12View SEC Filing  
3/27/2014Leaf Ventures Ii L.P. NewDirectorBuy60,000$21.02$1,261,200.00View SEC Filing  
3/26/2014Aisling Capital Iii LpMajor ShareholderBuy60,000$21.00$1,260,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Versartis (NASDAQ:VSAR)
DateHeadline logoVersartis : VSAR) Completes Enrollment in Phase III VELOCITY Trial of Somavaratan for the Treatment of Pediatric GHD (NASDAQ:VSAR) - August 27 at 7:13 AM logoNew Market Report: Versartis, Inc. (VSAR) - Financial and Strategic SWOT Analysis Review (NASDAQ:VSAR) - August 25 at 7:19 AM logoVersartis (VSAR) Completes Phase 3 VELOCITY Trial Enrollment (NASDAQ:VSAR) - August 22 at 8:05 PM logoVersartis Inc.: Teijin Limited and Versartis Enter Strategic Alliance for Commercialization of Somavaratan Long-Acting Growth Hormone in Japan (NASDAQ:VSAR) - August 10 at 11:26 AM logoVersartis (VSAR), Teijin Enter Strategic Alliance for Somavaratan in Japan (NASDAQ:VSAR) - August 10 at 11:26 AM logoTeijin Limited and Versartis Enter Strategic Alliance for Commercialization of Somavaratan Long-Acting Growth Hormone in Japan (NASDAQ:VSAR) - August 9 at 8:32 PM logoVersartis to Present at the Canaccord Genuity 36th Annual Growth Conference (NASDAQ:VSAR) - August 4 at 11:28 AM logoVersartis Reports Second Quarter 2016 Financial Results (NASDAQ:VSAR) - July 29 at 11:14 AM logoVersartis' Long-Acting Somavartan Could Replace Current Treatments In Growth Hormone Deficiency (NASDAQ:VSAR) - July 29 at 11:14 AM logoVersartis reports 2Q loss (NASDAQ:VSAR) - July 28 at 5:59 PM logoLpath (LPTN), Arcadia (RKDA), Helios (HMNY) Post Biggest Moves today (NASDAQ:VSAR) - June 14 at 6:37 AM logoVERSARTIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:VSAR) - June 3 at 6:09 AM logoVersartis, Inc. :VSAR-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 (NASDAQ:VSAR) - June 2 at 1:03 PM logoVersartis Inc (VSAR) is Trading Higher on Unusual Volume for May 23 - (NASDAQ:VSAR) - May 25 at 2:47 PM logoVersartis Inc (VSAR) Jumps 8.38% on May 23 - (NASDAQ:VSAR) - May 25 at 2:47 PM logoVERSARTIS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:VSAR) - May 23 at 4:03 PM logoVersartis Inc (VSAR) Jumps 5.89% on May 16 - (NASDAQ:VSAR) - May 19 at 2:32 PM logoVersartis Inc (VSAR) Jumps 5.69% on May 09 - (NASDAQ:VSAR) - May 11 at 8:30 AM
News IconVersartis Inc (VSAR) Receives “Buy” Rating from Canaccord Genuity - Washington News Wire (NASDAQ:VSAR) - May 11 at 8:30 AM
News IconLatest Analyst Ratings For Versartis, Inc. (NASDAQ:VSAR) - Share Trading News (NASDAQ:VSAR) - May 6 at 9:06 AM logoVersartis Inc (VSAR) Drops 6.37% on May 03 - (NASDAQ:VSAR) - May 6 at 9:06 AM logoVersartis Inc (VSAR) is Trading Lower on Unusual Volume for May 04 - (NASDAQ:VSAR) - May 6 at 9:06 AM
News IconHow Analysts Feel About Versartis Inc (NASDAQ:VSAR)? - B.O.D.Y Confidential (NASDAQ:VSAR) - May 4 at 7:41 AM logoVERSARTIS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:VSAR) - May 4 at 6:14 AM logoVersartis, Inc. (NASDAQ:VSAR) ABR of 1.67 - Investor Newswire (NASDAQ:VSAR) - May 1 at 8:51 AM logoVersartis reports 1Q loss (NASDAQ:VSAR) - April 28 at 6:29 PM logo4:56 pm Versartis reports Q1 EPS of ($0.82) vs. ($0.77) Capital IQ consensus (NASDAQ:VSAR) - April 28 at 4:56 PM logoVersartis Reports First Quarter 2016 Financial Results (NASDAQ:VSAR) - April 28 at 4:36 PM
News IconVersartis, Inc. (VSAR) Files Form 4 Insider Selling : Paul Westberg Sells 1430 Shares - Market Digest (NASDAQ:VSAR) - April 27 at 10:32 AM
News IconVersartis, Inc. (NASDAQ:VSAR) Latest Broker Views - Risers & Fallers (NASDAQ:VSAR) - April 27 at 10:32 AM
News IconRecently Changed Price Targets On Versartis, Inc. (NASDAQ:VSAR) - Risers & Fallers (NASDAQ:VSAR) - April 23 at 9:26 AM logoVersartis, Inc. (NASDAQ:VSAR) Has An Average Rating Of 3 - Investor Newswire (NASDAQ:VSAR) - April 19 at 10:30 AM logoUWM's Holdings Imply 12% Gain Potential (NASDAQ:VSAR) - April 15 at 1:01 PM
News IconVersartis, Inc. (NASDAQ:VSAR) Broker Price Targets For The Coming Week - Share Trading News (NASDAQ:VSAR) - April 12 at 1:00 PM
News IconVersartis, Inc. (NASDAQ:VSAR) Updated Broker Price Targets - Share Trading News (NASDAQ:VSAR) - April 9 at 12:26 PM
News IconHow Analysts Rated Versartis Inc (NASDAQ:VSAR) Last Week? - (NASDAQ:VSAR) - April 9 at 12:26 PM
News IconCormorant Asset Management Exits Position in Versartis Inc (VSAR) - Street Edition (NASDAQ:VSAR) - April 8 at 1:10 PM logoVersartis Inc (VSAR) Jumps 11.44% on April 06 - (NASDAQ:VSAR) - April 8 at 1:10 PM
News IconVersartis, Inc. (NASDAQ:VSAR) Updated Analyst Coverage - Risers & Fallers (NASDAQ:VSAR) - April 7 at 1:31 PM
News IconVersartis Inc (VSAR) Earns “Buy” Rating from Canaccord Genuity - MicroCap Magazine (NASDAQ:VSAR) - April 6 at 3:08 PM
News IconVersartis Incorporated (NASDAQ:VSAR) Shorted Shares Decreased By 2.54% - (NASDAQ:VSAR) - April 5 at 2:34 PM logoVersartis (VSAR) Shares March Higher, Can It Continue? (NASDAQ:VSAR) - April 4 at 9:51 AM logoVERSARTIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:VSAR) - April 4 at 8:36 AM
News IconPerceptive Advisors Lowers stake in Versartis Inc (VSAR) - Everything HUDSON (NASDAQ:VSAR) - April 3 at 2:20 PM logoVersartis Inc (VSAR) Jumps 14.92% on March 29 - (NASDAQ:VSAR) - April 1 at 2:57 PM logoVersartis Presents Confirmatory 18-Month Adherence Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting (NASDAQ:VSAR) - April 1 at 7:13 AM logoVERSARTIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (NASDAQ:VSAR) - April 1 at 7:06 AM logoVersartis Appoints Colin Hislop, M.D., as Chief Medical Officer (NASDAQ:VSAR) - March 30 at 8:41 AM
News IconVersartis Incorporated (NASDAQ:VSAR) Short Interest Increased By 1.31% - (NASDAQ:VSAR) - March 26 at 2:17 PM logoVERSARTIS, INC. Financials (NASDAQ:VSAR) - March 11 at 1:04 PM


Versartis (NASDAQ:VSAR) Chart for Monday, August, 29, 2016

Last Updated on 8/29/2016 by Staff